作者: Mariana Brait , Myriam Loyo , Eli Rosenbaum , Kimberly L. Ostrow , Alina Markova
DOI: 10.4161/EPI.20524
关键词: DNA methylation 、 Bisulfite sequencing 、 Cancer research 、 Thyroid 、 Methylation 、 Thyroid cancer 、 Candidate gene 、 Epigenetics 、 Cancer 、 Biology
摘要: Our aim was to comprehensively analyze promoter hypermethylation of a panel novel and known methylation markers for thyroid neoplasms establish their relationship with BRAF mutation clinicopathologic parameters cancer. A cohort tumors, consisting 44 cancers benign lesions, as well 15 samples adjacent normal tissue, evaluated hypermethylation. Genes quantitative specific PCR (QMSP) were selected by candidate gene approach. Twenty-two genes tested: TSHR, RASSF1A, RARβ2, DAPK, hMLH1, ATM, S100, p16, CTNNB1, GSTP1, CALCA, TIMP3, TGFsR2, THBS1, MINT1, MT1G, PAK3, NISCH, DCC, AIM1 KIF1A. The PCR-based "mutector assay" used detect mutation. All p values reported are two sided. Considerable overlap seen in the among different tissue groups. Significantly higher frequency level observed KIF1A RARs2 cancer compared tumors. negative correlation between RASSF1A methylation, positive accordance previous results. In addition, TIMP3 marginal DCC observed. present study constitutes comprehensive profile neoplasia shows that results must be analyzed tissue-specific manner identify clinically useful markers. Integration genetic epigenetic changes will help relevant biologic pathways drive its development.